Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 vs Rituximab in Idiopathic Membranous Nephropathy
CTR20200969Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Iptacopan in idiopathic membranous glomerulonephritis (IMG), sponsored by Novartis. Started Jul 2020; status: terminated.
02
Drugs
Iptacopan
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20200969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200969.